📣 WHO invites feedback on the draft Guidance on Evidence Generation for TB Preventive Treatment (GEG-TPT) — open for public comment until 1 August 2025.

Help shape future @WHO guidelines on #TB prevention.

WHO Newsflash here:
buff.ly/zaIVweX

WHO launches an update on the consolidated guidelines to diagnose #tuberculosis
createsend.com/t/d-CCE83795...

Many thanks again to the fantastic group of people who contributed to the development of the document!

Last year we released WHO Guidance on evidence generation (GEG) on new regimens for #TB treatment — a first-of-its-kind document that provides advise on how evidence should be generated to optimally inform WHO guideline development:
bsky.app/profile/sgsc...
www.who.int/publications...

Here two key messages from the GEG document that are particularly relevant to what you write about. Fully agree that composite outcomes --especially if they aggregate across very different outcomes-- can be misleading. That is why we don't do that when we evaluate data from TB treatment trials.

Thanks Tom for writing and flagging this -- gives me an opportunity to highlight guidance we released end of last year. One of the things we explain in the 'Guidance on evidence generation' (GEG) document is how we evaluate trial outcomes during guideline development: www.who.int/publications...

Great to see more data coming out from programmatic implementation of BPaLM (Belarus, Uzbekistan, Pakistan): ~800 patients & >90% success rate!

pubmed.ncbi.nlm.nih.gov/39964841/
pubmed.ncbi.nlm.nih.gov/39544887/

No FU post-Rx completion since based on routine data - but still good to see this

It was a great pleasure to talk about our work -- here an overview of the 21 key messages from the guidance and the link to the full document:
iris.who.int/bitstream/ha...

It outlines 21 key messages, explains why they are important, and what approaches can increase the chances of research leading to strong WHO recommendations. The key messages cover areas such as trial design, selection criteria, outcome choice, sample size, ...

Today WHO released Guidance on evidence generation (GEG) on new regimens for #TB treatment — a first-of-its-kind document that advises researchers, developers, funders, and other stakeholders about how evidence should be generated to optimally inform WHO guideline development.

Here some key areas where the new WHO guidance provides important support towards improved evidence generation through clinical trials

In the coming weeks we will release 'Guidance on evidence generation (GEG) on new regimens for tuberculosis treatment' -- a first-of-its-kind WHO document.

Interim results from endTB-Q: 6-9m BDCL (86%) vs 18m standard of care regimen (88%) favorable outcomes. A lot more to unpack...
https://buff.ly/4fCqO3z
https://buff.ly/3YZTJZT

Protocol here:
https://buff.ly/40BhHMo

New guidance document on clinical trials just published by WHO. Strongly encourage anyone working on clinical trials to read this document https://buff.ly/3XWHRap

"In 2023, Tuberculosis (TB) probably returned to being the world’s leading cause of death from a single infectious agent, following 3 years in which it was replaced by coronavirus disease (COVID-19), and caused almost twice as many deaths as HIV/AIDS."
https://buff.ly/3C3Hsuw

Otsuka announcing their plans for a Phase 3 trial of their novel #TB drug Quabodepistat (sorry for the poor resolution). Good to see one of the novel drugs move ahead to a registrational trial!

Updated clinical pipeline by the Working Group for New Drugs - @newtbdrugs
https://buff.ly/3Atygzg